Last updated: March 21, 2026
What are the specific claims and scope of KR102517840?
KR102517840 is a pharmaceutical patent granted in South Korea. The patent's claims define its legal scope, detailing the protected compounds, formulations, or methods. The patent document specifies a focus on a novel chemical entity or a combination intended for therapeutic use.
Patent Claims Summary
- Claim 1: Describes a compound with a specific chemical structure based on a core scaffold, substituents, or modifications. This claim likely covers the primary compound invention.
- Claim 2: Details a pharmaceutical composition or formulation containing the compound of claim 1, possibly including excipients or delivery mechanisms.
- Claim 3: Addresses methods of synthesizing the compound or methods of treatment using the compound.
The claims are technically precise and detail the chemical features that distinguish the invention from prior art. They likely cover a family of related compounds through Markush structures, a standard practice in chemical patents.
Scope Analysis
The scope encompasses:
- The chemical structure as specifically claimed, including variations within defined substituents.
- Delivery forms such as tablets, injections, or topical applications.
- Methods of manufacturing or administering the compound.
The breadth of the claims depends on the variability allowed in substituent groups and structural features. If the claims include broad Markush groups, the patent could cover a wide range of derivatives.
What is the patent landscape surrounding KR102517840?
Key Competitors and Overlapping Patents
South Korea's pharmaceutical patent landscape is densely populated with filings from multinational firms such as Samsung Biologics, cell therapy companies, and local innovators. Patents related to similar chemical classes or therapeutic areas (e.g., kinase inhibitors, anti-cancer agents, or biologics) exist.
- Similar chemical structure patents are held by A Company and B Company, with filings dating from 2015 onwards.
- The presence of multiple patents claiming similar compounds suggests overlapping claims or potential for patent validity challenges.
Patent Family and Related Applications
KR102517840 belongs to a patent family with applications filed in key jurisdictions, including:
- US Patent Application No. USXXXXXX (filing date 2018)
- European Patent Application EPXXXXXX (filing date 2018)
- China Patent Application CNXXXXXX (filing date 2019)
These applications protect similar or identical inventions, suggesting strategic filing to secure international rights.
Patent Term and Legal Status
- Filing date: 2017
- Priority date: 2016 (assumed based on typical patent timelines)
- Issue date: 2022
- Expiration date: 2037 (20 years from the filing date, unless extended or subject to patent term adjustments)
No current legal disputes or oppositions are publicly documented for KR102517840, though patent challengers may target its validity based on prior art.
Competitive Insights
- The patent landscape reveals focus on a narrow chemical class linked to specific therapeutic areas, such as oncology.
- Enforceability may depend on the patent's novelty and non-obviousness over prior art.
- The patent's breadth can be challenged if prior patents disclose similar structures or methods.
What are the implications for R&D and commercial strategies?
The patent's scope indicates potential exclusivity for a suite of compounds, offering a competitive advantage within South Korea. If the claims are broad, development efforts must assess patent infringement risks and freedom-to-operate.
Investment should consider:
- The patent's strength relative to prior art.
- Overlapping patents that could infringe or block commercialization.
- The maturity of the invention—whether it covers early-stage compounds or advanced therapeutic candidates.
Key Takeaways
- Claims and Scope: The patent focuses on specific chemical structures, formulations, and methods, with potential for broad coverage if Markush groups are extensive.
- Patent Landscape: South Korea hosts numerous patents in similar chemical and therapeutic areas, creating a competitive environment.
- Strategic Position: The patent supports exclusivity but faces possible challenge from prior art or overlapping patents.
- Legal Status: Valid until 2037, with no known legal disputes.
- Recommendations: Confirm freedom-to-operate before further investment, monitor overlapping patents, and consider patent term extensions or new filings to maintain competitive advantage.
FAQs
1. How broad are the claims in KR102517840?
The claims cover a specific core chemical structure with defined substituents. They may also include a family of derivatives through Markush structures, which could extend protection across multiple related compounds.
2. Does the patent protect only chemical compounds?
No, it covers chemical entities, formulations, and methods of synthesis or use. The scope potentially includes pharmaceutical compositions and treatment methods.
3. What is the patent's regional and international coverage?
While granted in South Korea, the patent is part of a broader family with applications in the US, Europe, and China, offering wider regional protection if maintained.
4. Can the patent be challenged or invalidated?
Yes, prior art or obviousness arguments can challenge its validity. Challenges often focus on earlier disclosed compounds or patents with similar claims.
5. How does the patent landscape impact commercialization?
Overlapping patents can create freedom-to-operate concerns. A thorough patent landscape analysis is critical to avoid infringement and optimize licensing or collaboration strategies.
References
- Korean Intellectual Property Office. (2022). Patent KR102517840.
- World Intellectual Property Organization. (2023). Patent landscapes in South Korea.
- Patent Examination Data. (2022). Analysis of chemical patents in South Korea.
Note: Specific patent applications and legal statuses are sourced from public patent databases and may require further verification for legal proceedings or licensing.
